批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/11/24 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/05/09 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/05/09 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/03/20 |
SUPPL-35(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/09/30 |
SUPPL-34(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/03/23 |
SUPPL-31(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/02/19 |
SUPPL-32(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/09/11 |
SUPPL-30(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/05/18 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/03/15 |
SUPPL-28(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/18 |
SUPPL-27(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2011/05/13 |
SUPPL-26(补充) |
Approval |
REMS |
N/A
|
|
|
2010/08/04 |
SUPPL-24(补充) |
Approval |
REMS |
N/A
|
|
|
2008/12/19 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2008/07/18 |
SUPPL-20(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2007/05/07 |
SUPPL-19(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/08/11 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/08/02 |
SUPPL-14(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2004/07/26 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/04/15 |
SUPPL-13(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2003/07/17 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/24 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2002/10/02 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/08/14 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/06/04 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/01/28 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/07/13 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2000/12/15 |
SUPPL-2(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2000/07/27 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2000/04/20 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1998/12/17 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:ABACAVIR SULFATE 剂型/给药途径:SOLUTION;ORAL 规格:EQ 20MG BASE/ML 治疗等效代码:AA
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020978 |
001 |
NDA |
ZIAGEN |
ABACAVIR SULFATE |
SOLUTION;ORAL |
EQ 20MG BASE/ML |
Prescription |
Yes |
Yes |
AA |
1998/12/17
|
VIIV HLTHCARE |
201107 |
001 |
ANDA |
ABACAVIR SULFATE |
ABACAVIR SULFATE |
SOLUTION;ORAL |
EQ 20MG BASE/ML |
Prescription |
No |
No |
AA |
2016/09/26
|
HETERO LABS LTD III |
077950 |
001 |
ANDA |
ABACAVIR SULFATE |
ABACAVIR SULFATE |
SOLUTION;ORAL |
EQ 20MG BASE/ML |
Prescription |
No |
No |
AA |
2018/03/14
|
AUROBINDO PHARMA LTD |